Home › Aortic Valve Stenosis › NCT07556523

Patient Quality of Recovery After TAVR With Different Sedation Regimens

Who can join

Ages 18 to 90 · All sexes

Inclusion Criteria:

* 18-90 years old, inclusive
* Undergoing transfemoral TAVR under Monitored Anesthesia Care (MAC)
* Speaks English or Spanish
* Consents to participate

Exclusion Criteria:

* Preoperative heart rate \< 50 bpm or arrhythmias (e.g., AFib with RVR)
* Conduction abnormalities (e.g., 2nd/3rd degree AV block without pacer)
* Allergy or contraindication to study drugs
* Pulmonary artery pressure \> 70mmHg
* Morbid obesity BMI \> 50
* Pregnancy
* Unable to consent in English or Spanish

About the study

The goal of this clinical trial is to learn whether the type of sedation medication used during a transcatheter aortic valve replacement (TAVR) affects how people recover after the procedure. The main question this study aims to answer is whether different sedation regimens (propofol, dexmedetomidine, or midazolam with fentanyl) lead to differences in quality of recovery on the first day after the procedure.

Researchers will compare three commonly used sedation medications (propofol, dexmedetomidine, or midazolam with fentanyl) to determine whether they lead to differences in recovery following a TAVR.

Participants will:

* Be enrolled before their scheduled TAVR procedure * Be randomly assigned to receive one of the three sedation medications during their procedure * Complete short surveys on postoperative days 1 and 7 about pain levels, how they feel during their recovery, and how satisfied they were with their anesthesia experience

What is being tested

• Propofol (drug)
• Dexmedetomidine (drug)
• Midazolam (drug)
• Fentanyl (drug)

Sponsor: David Lyubashevsky · Participants: 126 · Started: Mar 16, 2026

Contact the study team

• Jessica Brickner · Phone: 847-570-1197
• Nia Moragne · Phone: 847-570-1197

Official record on ClinicalTrials.gov — NCT07556523

Locations in the U.S.

Conditions

• Aortic Valve Stenosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.